## Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 3

#### ENDO PHARMACEUTICALS HOLDINGS INC

Form 3 April 20, 2006

## FORM 3

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, Expires: 2005

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \* À DE ROSEN MICHEL

(Last) (First) (Middle)

C/O VIROPHARMA **INCORPORATED.Â** 397 **EAGLEVIEW BLVD** 

(Street)

EXTON. PAÂ 19341

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Statement

(Month/Day/Year) 04/19/2006

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

(Check all applicable)

X Director 10% Owner Officer Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

4. Nature of Indirect Beneficial

#### Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D)

(I)

Ownership (Instr. 5)

or Indirect (Instr. 5)

Common stock, par value \$0.01 per share

0

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

5. 4. Conversion or Exercise Price of Derivative

6. Nature of Indirect Beneficial Ownership Ownership Form of (Instr. 5)

### Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
2000 Stock Incentive Plan Options	(1)	04/19/2016	Common Stock	10,000 (2)	\$ 32.6	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
<b>.</b>	Director	10% Owner	Officer	Other		
DE ROSEN MICHEL						
C/O VIROPHARMA INCORPORATED	î v	Â	â	â		
397 EAGLEVIEW BLVD	АЛ	A	A	A		
EXTON Â PA Â 19341						

# **Signatures**

/s/ Caroline B.
Manogue

\*\*Signature of Reporting

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable 25% per year on each of April 19, 2007, April 19, 2008, April 19, 2009 and April 19, 2010.
- (2) These stock options were granted to Mr. de Rosen in consideration of his services on the Endo Pharmaceuticals Holdings Inc. Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2